GLP-1s Target Addiction: The Next Frontier for Incretin Therapies
GLP-1 receptor agonists, already dominant in diabetes and obesity, are being investigated for their potential to treat substance use disorders. Early clinical observations and pilot studies suggest these drugs may dampen the brain's reward system, offering a new mechanism for tackling addiction.